How big is Ligand Pharmaceuticals, Inc.?

As of Jun 18, Ligand Pharmaceuticals, Inc. has a market capitalization of $2.17 billion, with net sales of $181.48 million and a net profit of -$132.62 million over the last four quarters. Shareholder's funds are reported at $830.44 million, and total assets amount to $941.77 million.

As of Jun 18, Ligand Pharmaceuticals, Inc. has a market capitalization of 2,171.37 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 181.48 million, while the sum of net profit for the same period is -132.62 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 830.44 million, and the total assets amount to 941.77 million.

What does Ligand Pharmaceuticals, Inc. do?

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that develops and acquires technologies to aid in drug discovery and development. As of March 2025, it reported net sales of $45 million and a net loss of $42 million, with a market cap of approximately $2.17 billion.

Overview:<BR>Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing and acquiring technologies to assist pharmaceutical companies in discovering and developing medicines, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 45 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -42 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2,171.37 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.26 <BR>Return on Equity: -9.97% <BR>Price to Book: 2.73<BR><BR>Contact Details:<BR>Address: 3911 Sorrento Valley Blvd Ste 110, SAN DIEGO CA: 92121-1402 <BR>Tel: 1 858 5507500 <BR>Website: https://www.ligand.com/

Should I buy, sell or hold Ligand Pharmaceuticals, Inc.?

Who are in the management team of Ligand Pharmaceuticals, Inc.?

As of March 2022, the management team of Ligand Pharmaceuticals, Inc. includes Dr. John Kozarich (Non-Executive Independent Chairman), Mr. John Higgins (CEO and Director), and several Independent Directors: Mr. Jason Aryeh, Ms. Sarah Boyce, Mr. Todd Davis, and Dr. Nancy Gray. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Ligand Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. John Kozarich, who serves as the Non-Executive Independent Chairman of the Board.<BR>- Mr. John Higgins, the Chief Executive Officer and a Director.<BR>- Mr. Jason Aryeh, an Independent Director.<BR>- Ms. Sarah Boyce, an Independent Director.<BR>- Mr. Todd Davis, an Independent Director.<BR>- Dr. Nancy Gray, an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is Ligand Pharmaceuticals, Inc. overvalued or undervalued?

As of February 27, 2025, Ligand Pharmaceuticals is considered overvalued with high valuation ratios and negative returns on capital and equity, despite a strong year-to-date stock performance of 58.50%.

As of 27 February 2025, Ligand Pharmaceuticals, Inc. has moved from an attractive to a risky valuation grade. The company appears to be overvalued, given its high valuation ratios, including a Price to Book Value of 2.57, an EV to Sales ratio of 10.12, and an EV to EBITDA ratio of 88.07. In comparison to peers, TG Therapeutics, Inc. has a P/E ratio of 83.91, while Catalyst Pharmaceuticals, Inc. stands out with a much lower P/E of 12.14, indicating that Ligand is trading at a premium relative to its industry.<BR><BR>Despite this overvaluation, Ligand has shown strong stock performance, with a year-to-date return of 58.50% compared to the S&P 500's 12.22%. However, the significant losses reflected in its negative ROCE of -2.83% and ROE of -9.97% further underscore the risks associated with its current valuation.

Is Ligand Pharmaceuticals, Inc. technically bullish or bearish?

As of July 18, 2025, Ligand Pharmaceuticals has a bullish technical trend supported by positive MACD and Bollinger Bands indicators, despite a bearish weekly RSI, and has significantly outperformed the S&P 500 year-to-date and over the past year.

As of 18 July 2025, the technical trend for Ligand Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, supporting the overall positive stance. The Bollinger Bands are also bullish on both weekly and monthly time frames. However, the weekly RSI is bearish, indicating some short-term weakness. Moving averages are bullish on a daily basis, and the KST is bullish on both weekly and monthly levels. Dow Theory shows a mildly bullish stance on both weekly and monthly time frames, while the OBV is mildly bearish weekly but bullish monthly.<BR><BR>In terms of performance, Ligand Pharmaceuticals has outperformed the S&P 500 across multiple periods, with a year-to-date return of 58.50% compared to the S&P 500's 12.22%, and a one-year return of 63.80% versus 17.14%. Overall, the current technical stance is bullish, with strong indicators supporting this view, despite some short-term bearish signals from the RSI.